Since CD20 is a marker for less mature B cells while CD19 is a marker for more differentiated B cells [188], CD19 targeted therapies are believed to have more comprehensive coverage of B cell lineages that fall under different growth stages and therefore offer greater potential to cure autoimmune diseases. This evidence concerns the gene CD19 and autoimmune disease.